Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity

Simple item page
dc.contributor.authorQuddos, Fatimaen
dc.contributor.authorHubshman, Zacharyen
dc.contributor.authorTegge, Allisonen
dc.contributor.authorSane, Danielen
dc.contributor.authorMarti, Erinen
dc.contributor.authorKablinger, Anita S.en
dc.contributor.authorGatchalian, Kirstin M.en
dc.contributor.authorKelly, Amber L.en
dc.contributor.authorDiFeliceantonio, Alexandra G.en
dc.contributor.authorBickel, Warren K.en
dc.date.accessioned2024-01-08T21:31:37Zen
dc.date.available2024-01-08T21:31:37Zen
dc.date.issued2023en
dc.description.abstractAlcohol Use Disorder (AUD) contributes significantly to global mortality. GLP-1 (Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) agonists, FDA-approved for managing type 2 diabetes and obesity, where the former has shown to effectively reduce the consumption of alcohol in animal models but no reports exist on the latter. In this report, we conducted two studies. In the first study, we conducted an analysis of abundant social media texts. Specifically, a machine-learning based attribution mapping of ~ 68,250 posts related to GLP-1 or GLP-1/GIP agonists on the Reddit platform. Secondly, we recruited participants (n = 153; current alcohol drinkers; BMI ≥ 30) who self-reported either taking Semaglutide (GLP-1 agonist), Tirzepatide (the GLP-1/GIP combination) for ≥ 30 days or, as a control group; no medication to manage diabetes or weight loss for a within and between subject remote study. In the social media study, we report 8 major themes including effects of medications (30%); diabetes (21%); and Weight loss and obesity (19%). Among the alcohol-related posts (n = 1580), 71% were identified as craving reduction, decreased desire to drink, and other negative effects. In the remote study, we observe a significantly lower self-reported intake of alcohol, drinks per drinking episode, binge drinking odds, Alcohol Use Disorders Identification Test (AUDIT) scores, and stimulating, and sedative effects in the Semaglutide or Tirzepatide group when compared to prior to starting medication timepoint (within-subjects) and the control group (between-subjects). In summary, we provide initial real-world evidence of reduced alcohol consumption in people with obesity taking Semaglutide or Tirzepatide medications, suggesting potential efficacy for treatment in AUD comorbid with obesity.en
dc.description.sponsorshipFralin Biomedical Research Institute at Virginia Tech Carillionen
dc.identifier.doihttps://doi.org/10.1038/s41598-023-48267-2en
dc.identifier.urihttps://hdl.handle.net/10919/117318en
dc.identifier.volume13en
dc.language.isoen_USen
dc.publisherNature Portfolioen
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.titleSemaglutide and Tirzepatide reduce alcohol consumption in individuals with obesityen
dc.title.serialScientific Reportsen
dc.typeArticle - Refereeden

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
s41598-023-48267-2.pdf
Size:
1.82 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.5 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Scholarly Works, Fralin Biomedical Research Institute at VTC
Open Access Subvention Fund Articles